CA3248186A1 - GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Google Patents
GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASEInfo
- Publication number
- CA3248186A1 CA3248186A1 CA3248186A CA3248186A CA3248186A1 CA 3248186 A1 CA3248186 A1 CA 3248186A1 CA 3248186 A CA3248186 A CA 3248186A CA 3248186 A CA3248186 A CA 3248186A CA 3248186 A1 CA3248186 A1 CA 3248186A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- gpr120
- sulfamoyl
- heptanoic acid
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22160079.4 | 2022-03-03 | ||
| EP22160079.4A EP4238557A1 (en) | 2022-03-03 | 2022-03-03 | Gpr120 agonists for the treatment of inflammatory bowel disease |
| PCT/EP2023/055490 WO2023166203A1 (en) | 2022-03-03 | 2023-03-03 | Gpr120 agonists for the treatment of inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248186A1 true CA3248186A1 (en) | 2023-09-07 |
Family
ID=80628869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248186A Pending CA3248186A1 (en) | 2022-03-03 | 2023-03-03 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250177329A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4238557A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507962A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119031908A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248186A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314689A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023166203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120919101A (zh) * | 2025-09-26 | 2025-11-11 | 南京农业大学 | Gw9508在制备治疗轮状病毒的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3281937A1 (en) * | 2016-08-09 | 2018-02-14 | Dompé farmaceutici S.p.A. | Sulfonamides as gpr40- and gpr120-agonists |
| CN111317728A (zh) * | 2018-12-14 | 2020-06-23 | 中国科学院大连化学物理研究所 | 天然来源ffa4(gpr120)受体激动剂及其应用 |
-
2022
- 2022-03-03 EP EP22160079.4A patent/EP4238557A1/en not_active Withdrawn
-
2023
- 2023-03-03 EP EP23708797.8A patent/EP4486327A1/en active Pending
- 2023-03-03 WO PCT/EP2023/055490 patent/WO2023166203A1/en not_active Ceased
- 2023-03-03 CN CN202380023191.0A patent/CN119031908A/zh active Pending
- 2023-03-03 US US18/843,373 patent/US20250177329A1/en active Pending
- 2023-03-03 IL IL314689A patent/IL314689A/en unknown
- 2023-03-03 JP JP2024552421A patent/JP2025507962A/ja active Pending
- 2023-03-03 CA CA3248186A patent/CA3248186A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486327A1 (en) | 2025-01-08 |
| EP4238557A1 (en) | 2023-09-06 |
| WO2023166203A1 (en) | 2023-09-07 |
| CN119031908A (zh) | 2024-11-26 |
| US20250177329A1 (en) | 2025-06-05 |
| JP2025507962A (ja) | 2025-03-21 |
| IL314689A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005271878B2 (en) | Compositions for delivering peptide YY and PYY agonists | |
| WO2015147240A1 (ja) | 敗血症の予防治療剤 | |
| JP3667381B2 (ja) | 解熱鎮痛剤 | |
| EP2059234B1 (en) | Method for reducing or alleviating inflammation in the digestive tract | |
| CN101674823A (zh) | 用于与增强的5-脂氧合酶和/或白三烯活性有关的疾病(例如哮喘)的r-齐留通 | |
| KR20210100594A (ko) | 염증성 장애의 치료에 사용하기 위한 벤조이미다졸 유도체 | |
| US20250177329A1 (en) | Gpr120 agonists for the treatment of inflammatory bowel disease | |
| JP5567484B2 (ja) | 機能性消化管障害の予防及び/又は治療剤 | |
| JP5575927B2 (ja) | ペントキシフィリンの便秘の予防または治療における応用 | |
| AU2020386913A1 (en) | Methods for treating inflammatory bowel disease | |
| US11648240B2 (en) | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | |
| RU2829636C1 (ru) | Фармацевтическая композиция на основе 5-пентилрезорцинола для лечения воспалительных заболеваний кишечника | |
| WO2022051319A1 (en) | Fixed dose combinations of chs-131 and a dpp-4 inhibitor | |
| WO2021230264A1 (ja) | 胆道系疾患の診断補助・予防・治療剤 | |
| US10471005B2 (en) | Low dose pharmaceutical composition | |
| CN119405649A (zh) | 呋喃二烯酮在制备治疗炎症性肠病药物中的应用 | |
| JP5410816B2 (ja) | 小腸粘膜障害の予防・治療薬剤としての医薬組成物 | |
| IT201900019858A1 (it) | Composizione farmaceutica comprendente una combinazione sinergica di ibuprofene e N-acetilcisteina | |
| JP2009126813A (ja) | 口腔粘膜疾患の治療剤 | |
| WO2026008018A1 (zh) | 一类肝靶向的蛋白降解剂偶联物及其用途 | |
| EA045566B1 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
| CZ20022630A3 (cs) | Pouľití rofleponidu pro léčení syndromu dráľdivého střeva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240809 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20241016 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250115 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250115 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250214 |